Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers Journal Article
| Authors: | Luo, J.; Rizvi, H.; Egger, J. V.; Preeshagul, I. R.; Wolchok, J. D.; Hellmann, M. D. |
| Article Title: | Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers |
| Abstract: | The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether programmed death 1 (PD-1) blockade therapy affects severity of illness from COVID-19 in patients with cancer. To address this uncertainty, we examined consecutive patients with lung cancers who were diagnosed with COVID-19 and examined severity on the basis of no or prior receipt of PD-1 blockade. Overall, the severity of COVID-19 in patients with lung cancer was high, including need for hospitalization in more than half of patients and death in nearly a quarter. Prior PD-1 blockade was, as expected, associated with smoking status. After adjustment for smoking status, PD-1 blockade exposure was not associated with increased risk of severity of COVID-19. PD-1 blockade does not appear to affect the severity of COVID-19 in patients with lung cancers. SIGNIFICANCE: A key question in oncology practice amidst the COVID-19 pandemic is whether PD-1 blockade therapy affects COVID-19 severity. Our analysis of patients with lung cancers supports the safety of PD-1 blockade treatment to achieve optimal cancer outcomes. |
| Keywords: | t-cells |
| Journal Title: | Cancer Discovery |
| Volume: | 10 |
| Issue: | 8 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-01-01 |
| Start Page: | 1121 |
| End Page: | 1128 |
| Language: | English |
| ACCESSION: | WOS:000558688700021 |
| DOI: | 10.1158/2159-8290.Cd-20-0596 |
| PROVIDER: | wos |
| PMCID: | PMC7416461 |
| PUBMED: | 32398243 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work